Cargando…
AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients
Angiogenesis represents a rate-limiting step during tumor progression. Targeting angiogenesis is already applied in cancer treatment, yet limits of anti-angiogenic therapies have emerged, notably because tumors adapt and recur after treatment. Therefore, there is a strong need to better understand t...
Autores principales: | Langlois, Benoit, Saupe, Falk, Rupp, Tristan, Arnold, Christiane, van der Heyden, Michaël, Orend, Gertraud, Hussenet, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4279391/ https://www.ncbi.nlm.nih.gov/pubmed/25301723 |
Ejemplares similares
-
Advances in tenascin-C biology
por: Midwood, Kim S., et al.
Publicado: (2011) -
Tenascin-C: Exploitation and collateral damage in cancer management
por: Spenlé, Caroline, et al.
Publicado: (2015) -
AntAngioCOOL: computational detection of anti-angiogenic peptides
por: Zahiri, Javad, et al.
Publicado: (2019) -
AntiAngioPred: A Server for Prediction of Anti-Angiogenic Peptides
por: Ettayapuram Ramaprasad, Azhagiya Singam, et al.
Publicado: (2015) -
Microgravity Effects on the Matrisome
por: Buravkova, Ludmila, et al.
Publicado: (2021)